Real clinical setting intravenous ketamine use for treatment resistant depression: 12 month follow-up after initial response
Rev Psiquiatr Salud Ment (Engl Ed)
.
2021 Oct-Dec;14(4):227-229.
doi: 10.1016/j.rpsmen.2021.11.004.
Authors
Nora Olazabal
1
,
Sonia Bustamante
2
,
M Aranzazu Madrazo
2
,
Luis Osa
2
,
Ana M O'Neill Of Tyrone
2
,
Ana Catalán
3
,
Miguel Angel González-Torres
3
Affiliations
1
OSI Bilbao-Basurto. Hospital Basurto, Bilbao, Spain. Electronic address: nora.olazabaleizaguirre@osakidetza.net.
2
OSI Bilbao-Basurto. Hospital Basurto, Bilbao, Spain.
3
OSI Bilbao-Basurto. Hospital Basurto, Bilbao, Spain; Neuroscience Department, University of the Basque Country, Spain.
PMID:
34861931
DOI:
10.1016/j.rpsmen.2021.11.004
No abstract available
Publication types
Letter
MeSH terms
Antidepressive Agents / therapeutic use
Depressive Disorder, Treatment-Resistant* / drug therapy
Follow-Up Studies
Humans
Infusions, Intravenous
Ketamine* / therapeutic use
Substances
Antidepressive Agents
Ketamine